Results 91 to 100 of about 35,846 (211)

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan

Drugs - Real World Outcomes
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as a first-line therapy for type 2 diabetes in Japan. Precautions of the package inserts for ethical drugs containing DPP-4 inhibitors were revised for pemphigoid between 2016 and 2018.
Akina Takami, Gen Terashima, Takumi Tajima, Koki Yamashita, Ataru Igarashi   +4 more
doaj   +1 more source

Need an add-on to metformin? Consider this [PDF]

, 2017
Review of: Ou SM, Shih CJ, Chao PW, et al. Effects of clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med.
Lyon, Corey, Mounsey, Anne, Wyncott, David   +2 more
core  

Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact

Revista Peruana de Medicina Experimental y Salud Pública, 2014
Objectives. Determine the clinical repurcussions of adherence, metabolic control, hypoglycemia and cardiovascular events (CVE) and economics (resources and costs) in the combination therapy of metformin vs DPP-4 (dipeptidyl peptidase-4) inhibitors and ...
Antoni Sicras-Mainar, Ruth Navarro-Artieda   +1 more
doaj   +1 more source

Xenobiotic-induced activation of human aryl hydrocarbon receptor target genes in Drosophila is mediated by the epigenetic chromatin modifiers [PDF]

, 2017
Aryl hydrocarbon receptor (AHR) is the key transcription factor that controls animal development and various adaptive processes. The AHR\u27s target genes are involved in biodegradation of endogenous and exogenous toxins, regulation of immune response ...
Akishina, Angelina A., Cherezov, Roman O., Enikolopov, Grigori N., Kuzin, Boris A., Mazo, Alexander M., Mertsalov, Ilja B., Panin, Vladislav M., Petruk, Svetlana, Simonova, Olga B., Slezinger, Mikhail S., Vorontsova, J. E., Zatsepina, Olga G.   +11 more
core   +1 more source

Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study

Diabetology & Metabolic Syndrome
Background To compare the effects of switching from dipeptidyl peptidase 4 (DPP-4) inhibitors to oral semaglutide on oxidative stress and glucose variability assessed by continuous glucose monitoring in patients with type 2 diabetes mellitus (T2DM ...
Makoto Ohara, Hiroki Yokoyama, Hiroaki Seino, Tomoki Fujikawa, Yo Kohata, Noriyuki Takahashi, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Tomoyasu Fukui, Sho-ichi Yamagishi   +10 more
doaj   +1 more source

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.

PLoS ONE, 2014
ObjectiveTo perform a systematic review and meta-analysis regarding the efficacy and safety of dipeptidyl peptidase-4 (DDP-4) inhibitors ("gliptins") for the treatment of type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment ...
Dongsheng Cheng, Yang Fei, Yumei Liu, Junhui Li, Yuqiang Chen, Xiaoxia Wang, Niansong Wang   +6 more
doaj   +1 more source

Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies

Molecules
The objective of this study was to identify multiple alkaloids in Coptis chinensis that demonstrate inhibitory activity against DPP-4 and systematically evaluate their activity and binding characteristics.
Zixi Zhao, Ruonan Ma, Yuqing Ma, Liqiang Zhao, Lele Wang, Yuzhen Fang, Yuxin Zhang, Xia Wu, Xing Wang   +8 more
doaj   +1 more source

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

Therapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K. Leong, Ching-Feng Weng   +6 more
doaj   +1 more source

Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis

Current Therapeutic Research
Background: To investigate the safety and efficiency of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetic kidney disease. Methods: We conducted a comprehensive literature search across multiple databases, including Embase, PubMed, CNKI,
Adili Tuersun, M.A., Munire Mohetaer, M.A., Guanxin Hou, B.A., Gang Cheng, Ph.D   +3 more
doaj   +1 more source

DPP-4 inhibitor [PDF]

, 2020
openaire   +1 more source